title: Cerebroprotective effects of angiotensin II (AT 1) receptor antagonists?
abstract: The results of the Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study show that treatment with an angiotensin receptor blocker (ARB) in the acute phase of a stroke improves mortality and cardiovascular morbidity. In addition, direct comparative antihypertensive trials have demonstrated beneficial effects of ARBs in preventing stroke. These possible cerebro-protective effects of ARBs are supported by animal studies, demonstrating that stimulation of the AT2 receptor was related to a reduction in both cerebral infarct size and mortality. In the present report, we review both pathophysiological and clinical evidence for possible cerebroprotective effects of ARBs, independent of their effect on blood pressure.
authors.forename: W
authors.initials: W
authors.lastname: Drenthen
authors.forename: A A
authors.initials: AA
authors.lastname: Voors
authors.forename: J L J
authors.initials: JL
authors.lastname: Kappelle
authors.forename: D J
authors.initials: DJ
authors.lastname: van Veldhuisen
keywords: angiotensin; cerebral ischaemia; cerebrovascular circulation; stroke